摘要
目的探讨经直肠超声引导个体化穿刺活检在前列腺癌诊断中的临床价值。方法选取97例疑似前列腺癌患者按照个体化穿刺方案确定穿刺方法作为个体化组，52例行6针系统穿刺活检的疑似前列腺癌患者作为对照组，对比两组活检阳性率和并发症发生情况。结果个体化组穿刺活检发现前列腺癌42例，阳性率43．3％（42／97），前列腺癌患者与非前列腺癌患者年龄、前列腺体积比较差异无统计学意义（P〉0．05），前列腺特异抗原（PSA）水平比较差异有统计学意义[（26．4±2．9）μg／L比（11．2±3．1）μg/L，P=0．0000]。对照组穿刺活检发现前列腺癌12例，阳性率23．1％（12／52），个体化组穿刺活检阳性率明显高于对照组，差异有统计学意义（P=0．014）；个体化组和对照组并发症发生率比较差异无统计学意义（P〉0．05）。结论经直肠超声引导个体化前列腺穿刺活检比6点系统穿刺活检方案首次活检阳性率高，且不增加并发症发生率，是一种安全有效的穿刺模式，值得临床推广应用。
Objective To investigate the clinical value of individualization of transrectal ultrasound guided prostate biopsy strategies for prostate cancer detection. Methods Ninety-seven patients who were considered having prostate cancer underwent individualization prostate biopsy strategies as individualization group. Fifty-two patients who were considered having prostate cancer underwent systemic 6-core prostate biopsy as control group. The detection rate of prostate cancer and rate of complications were compared between two groups. Results The detection rate of prostate cancer in individualization group was 43.3 % （42/97）, there was no significant difference in age and prostate volume between the prostate cancer patients and the non-prostate cancer patients （P 〉 0.05 ）, but the prostate specific antigen （PSA） level of the prostate cancer patients was significantly higher than that of the non-prostate cancer patients [ （26.4 ± 2.9） μg/L vs. （ 11.2 ± 3.1 ） μg/L, P = 0.0000 ]. The detection rate of prostate cancer in control group was 23.1% （ 12/52 ）, the detection rate of prostate cancer in individualization group was significantly higher than that in control group （P = 0.014）. There was no significant difference in the rate of complications between two groups（P 〉 0.05 ）. Conclusions The first detection rate of prostate cancer in individualization of transrectal ultrasound guided prostate biopsy strategies is higher than that by systemic 6-core prostate biopsy,and the rate of complications is not increased. The individualization of transrectal ultrasound guided prostate biopsy strategies for prostate cancer is good, safety, deserve clinical expansion.
出处
《中国医师进修杂志》
2012年第32期13-15,共3页
Chinese Journal of Postgraduates of Medicine
